FindTrial
Sign In

Rituxumab

DRUG3 trials

Sponsors

Hoffmann-La Roche, Sinocelltech Ltd.

Conditions

B-cell Non-Hodgkin LymphomaDLBCL - Diffuse Large B Cell LymphomaDiffuse Large B-cell Lymphoma

Phase 1

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
CompletedNCT03677141
Hoffmann-La RocheB-cell Non-Hodgkin Lymphoma
Start: 2019-03-08End: 2023-10-12Updated: 2024-12-18

Phase 3

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Active, not recruitingNCT04408638
Hoffmann-La RocheDiffuse Large B-cell Lymphoma
Start: 2021-02-23End: 2028-03-31Target: 270Updated: 2026-07-07
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RecruitingNCT07570823
Sinocelltech Ltd.DLBCL - Diffuse Large B Cell Lymphoma
Start: 2026-06-04End: 2029-04-01Target: 101Updated: 2026-08-13

Related Papers

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
Blood Advances2026-06-10
Multivariable analyses (MVAs) of overall survival (OS) in the phase 3 SUNMO, STARGLO, and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL).
Journal of Clinical Oncology2026-05-28
Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
Blood2025-11-03
Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
Blood2025-11-03
CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma
Blood2025-11-03
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
2025-10-012 citations
Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO.
Journal of Clinical Oncology2025-05-282 citations
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Blood Advances2025-02-056 citations
Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
Blood2024-11-051 citations
Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant
Blood2024-11-05
Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
Blood2024-11-05
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis
Blood2024-11-05
An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan
Blood2024-11-05
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
2024-11-0173 citations
Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL)
Blood2023-11-02
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Blood Advances2023-08-1531 citations
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Journal of Clinical Oncology2021-12-16277 citations
A PHASE III TRIAL OF GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GEMOX) VS RITUXIMAB PLUS GEMOX FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Hematological Oncology2021-06-011 citations
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Journal of Clinical Oncology2021-05-2010 citations
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma
Blood2020-11-0443 citations

1 more papers not shown